ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Comparison of renal function parameters and acute kidney injury incidence between vancomycin monotherapy and vancomycin-fosfomycin combination therapy in patients: a propensity score-matched analysis.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Vancomycin (VAN) is a first-line agent for methicillin-resistant Staphylococcus aureus (MRSA) infections, but it poses nephrotoxicity risks. While VAN-fosfomycin (FOS) combination shows synergistic efficacy and lower mutant prevention concentrations, its renoprotective effects compared to VAN alone remain unclear. This study aims to directly compare renal function parameters and acute kidney injury incidence between VAN monotherapy and VAN + FOS combination therapy. After propensity score matching of the initial 156 patients, 76 individuals were included in the final analysis; 38 were assigned to the vancomycin monotherapy group and 38 in the VAN + FOS combination group. Renal function parameters were recorded at 48 h and 72 h post-treatment, and the incidence of acute kidney injury (AKI) was compared between the two groups. Univariate analyses were performed to identify baseline factors associated with AKI. The VAN + FOS group had a significantly lower incidence of AKI compared to the VAN-alone group (5.26% vs. 21.05%, P = 0.04). Due to the limited number of AKI cases, multivariate adjustment was not possible. Univariate analysis revealed significant associations between AKI incidence and FOS combination therapy, age, and vancomycin trough concentration (P = 0.04, P = 0.00, and P = 0.02, respectively). These findings warrant validation in larger, prospective studies. Fosfomycin adjunct therapy was associated with a lower incidence of vancomycin-induced AKI. However, these associations should be interpreted cautiously and require validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.